معرفی
Professor Garry Blakely serves as Chair of Microbial Genetics and Biotechnology at the University of Edinburgh, where he has maintained an active research program since 1999. His work bridges fundamental bacterial genetics with translational applications in biomedicine and industrial biotechnology, focusing on pathogenic bacteria including Bacteroides, Clostridium, Staphylococcus, and Streptococcus.
His academic foundation includes:
- Ph.D. from Queens University of Belfast (1990)
- MRC postdoctoral research at University of Glasgow (1990-1994)
- MRC postdoctoral research at University of Oxford (1994-1998)
- Wellcome Trust RCD Fellowship (1998-2002)
Blakely's research centers on four interconnected themes: bacterial chromosome dynamics, restriction-modification systems, polysaccharide biosynthesis, and host-microbiome crosstalk. His laboratory pioneered genetic tools for manipulating anaerobic pathogens like B. fragilis and C. difficile, revealing mechanisms of DNA damage response critical to antibiotic efficacy. The landmark discovery of BfUbb—a bacterial ubiquitin homologue with antimicrobial properties—established a novel molecular link between gut microbiota and autoimmune disorders such as lupus and rheumatoid arthritis through antigenic mimicry.
Analysis of his 2013-2019 publications reveals consistent thematic evolution: early work focused on restriction-modification systems and chromosome biology, while later research expanded into microbiome-autoimmunity connections and biotechnological applications like antimicrobial coatings. His studies integrate genomic, biochemical, and clinical approaches across fundamental microbiology, immunology, and materials science.
Scientific recognition includes:
- Wellcome Trust RCD Fellowship
Blakely actively supervises PhD students and secures collaborative funding from medical research councils and industry partners. His projects translate basic discoveries into novel biotechnological solutions, including engineered bacterial strains for compound production and medical device coatings that prevent bacterial adhesion. Current grants support investigations into BfUbb's role in autoimmune pathogenesis and development of next-generation antimicrobials targeting anaerobic pathogens.
He leads a multidisciplinary research group within the University of Edinburgh's Roger Land Building, maintaining active collaborations with Queen's University Belfast and industrial partners to advance bacterial genetics research toward clinical and industrial applications.
